In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study
Authors' conclusion
Nevertheless, in-hospital mortality was higher than during the initial pandemic wave while 6-month post-discharge survival remained favourable (99.7%).
Study context
- Population
- Adults (aged ≥16 years) requiring extracorporeal membrane oxygenation (ECMO) respiratory support for COVID-19, 98 centres in 21 countries, from the second pandemic wave (Sept 15, 2020) to the end of the pandemic (March 21, 2023)
- Participants
- 3,860 adults · 98 centres · 21 countries
- Exposure
- In-hospital survivors vs non-survivors
- Survivorsn = 1,702reference
- Non-survivorsn = 2,158
- Outcome
- In-hospital and 6-month survival
Methodological detailsinternational, multicentre
- International
- Multicentre
Main finding
As reported in the abstract
In-hospital mortality
In-hospital mortality
55.9%
n=2158
Deaths occurring during ECMO support
81.2%
n=1752
Alive at 6 months follow-up among in-hospital survivors
99.7%
n=1697
Observational data: associations, not effects.
Further findings
Support duration · for both groups
Factors linked to in-hospital mortality (mixed-effects multivariable logistic regression)
- Older age, pre-ECMO renal failure, pre-ECMO vasopressor use, longer time from intubation to ECMO initiation, and complications (neurological events, sepsis, bowel ischaemia, renal failure, bleeding)
Symptoms at follow-up · 6 months
- Dyspnoea
- 501 [32.0%] of 1568
- Cardiac symptoms
- 122 [7.8%] of 1568
- Neurocognitive symptoms
- 168 [10.7%] of 1567
Baseline characteristics, non-survivors vs survivors
- More non-survivors had diabetes, hypertension, CVD and renal failure, and required more pre-ECMO inotropes and vasopressors
Original publication
In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study. Lancet Respir Med. Published 23 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →